Clinical trials
Metastatic Urothelial Cancer clinical trials
Below are recruiting metastatic urothelial cancer clinical trials, each written for real people, not researchers. We’re tracking 130 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT06405425RecruitingPhase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07480356RecruitingPhase 3
Testing a new bladder cancer treatment (TARA-002) vs standard chemo
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Queen Creek, ArizonaAges 18 years+ - NCT07019220RecruitingPhase 2
Chemoablation for low-risk bladder cancer
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
ViennaAges 18 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Gilbert, ArizonaAges 18 years+ - NCT07048457RecruitingPhase 2
Surgery after drug therapy for advanced bladder cancer that has spread to a few spots
This study tests whether adding surgery to remove the original bladder tumor and any remaining cancer spots can help people with advanced bladder cancer that has spread to only a few areas. It is for people who have already started a specific type of chemotherapy and whose cancer has not grown.
New Haven, ConnecticutAges 18 years+ - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT05037279RecruitingPhase 3
Testing BCG treatment for bladder cancer after full tumor removal
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Vancouver, British ColumbiaAges 18 years+ - NCT07751133RecruitingPhase 3
Hormone therapy dosing study for metastatic prostate cancer
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
ManchesterAges 18 years+ - NCT07023861Enrolling by invitationEarly Phase 1
New imaging test for HER2-positive cancers
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
Wuxi, JiangsuAges 15–75 - NCT07023848Enrolling by invitationEarly Phase 1
Imaging study for HER2-positive cancers using a special tracer
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
Wuxi, JiangsuAges 18–75 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT07232602RecruitingPhase 1/Phase 2
New drug combinations for advanced bladder cancer
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
San Francisco, CaliforniaAges 18 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04574960RecruitingPhase 3
Neoadjuvant chemotherapy before kidney/ureter cancer surgery
This Phase 3 trial studies giving cisplatin-based chemotherapy before surgery for certain newly diagnosed upper-urinary-tract urothelial cancers (kidney/ureter). It may help shrink the cancer and improve outcomes by treating microscopic disease earlier.
Ottawa, OntarioAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT05312671RecruitingPhase 2
Atezolizumab plus chemo for small cell bladder cancer
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Metastatic Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic urothelial cancer?
- Yes. Clin2 currently lists 130 recruiting metastatic urothelial cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic urothelial cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic urothelial cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.